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ABSTRACT
Axonally specific microtubule-associated protein tau is an
important component of neurofibrillary tangles found in AD
(Alzheimer’s disease) and other tauopathy diseases such as
CTE (chronic traumatic encephalopathy). Such tau aggregate
is found to be hyperphosphorylated and often proteolytically
fragmented. Similarly, tau is degraded following TBI (trau-
maticbraininjury).Inthepresentstudy,weexaminedthedual
vulnerability of tau to calpain andcaspase-3 under neurotoxic
and neurodegenerative conditions. We first identified three
novel calpain cleavage sites in rat tau (four-repeat isoform) as
Ser
130QLys
131,G l y
157QAla
158 and Arg
380QGlu
381.
Fragment-specific antibodies to target the major calpain-
mediated TauBDP-35K (35 kDa tau-breakdown product) and
the caspase-mediated TauBDP-45K respectively were
developed. In rat cerebrocortical cultures treated with
excitotoxin [NMDA (N-methyl-D-aspartate)], tau is signifi-
cantly degraded into multiple fragments, including a
dominant signal of calpain-mediated TauBDP-35K with
minimal caspase-mediated TauBDP-45K. Following apopto-
sis-inducing EDTA treatment, tau was truncated only to
TauBDP-48K/45K-exclusively by caspase. Cultures treated
with another apoptosis inducer STS (staurosporine), dual
fragmentation by calpain (TauBDP-35K) and caspase-3
(TauBDP-45K) was observed. Tau was also fragmented in
injured rat cortex following TBI in vivo to BDPs of 45–42 kDa
(minor), 35 kDa and 15 kDa, followed by TauBDP-25K.
Calpain-mediated TauBDP-35K-specific antibody confirmed
robust signals in the injured cortex, while caspase-mediated
TauBDP-45K-specific antibody only detected faint signals.
Furthermore, intravenous administration of a calpain-specific
inhibitor SNJ-1945 strongly suppressed the TauBDP-35K
formation. Taken together, these results suggest that tau
protein is dually vulnerable to calpain and caspase-3
proteolysis under different neurotoxic and injury conditions.
Key words: cell death, neurodegeneration, protease, tau
protein, tauopathy, traumatic brain injury (TBI).
INTRODUCTION
Axonally specific microtubule-associated protein tau is an
important factor in AD (Alzheimer’s disease) as tau aggregate
is found in a form of neurofibrillary tangle. Besides tau
hyperphosphorylation, proteolytic processing of tau was
suggested to facilitate tau deposit formation (Zemlan et al.,
2003; Gabbita et al., 2005; Arnaud et al., 2009). Similarly, tau
is also degraded following acute TBI (traumatic brain injury)
and with neurotoxin exposure in vitro and in vivo (e.g.
Methamphetamine and Ecstasy) (Warren et al., 2005, 2006,
2007; Arnaud et al., 2009). Siman et al. (2004) reported that
tau BDP (breakdown product) can be detected in neuronal
culture media following neurodegenerative challenge and in
CSF (colony-stimulating factor) from human TBI patients.
Several studies have also reported increased levels of tau
protein in CSF from brain-injured patients (Zemlan et al.,
2002; Franz et al., 2003) and from patients who experienced
ischaemic stroke (Bitsch et al., 2002). A cleaved form of tau
was specifically identified in the hippocampus, cortex after in
vivo kainite administration and a rat model of TBI (Zemlan et
al., 2003; Gabbita et al., 2005). However, the exact protease(s)
involved in c-tau formation has not been elucidated.
There are two cellular cysteine proteases (calpain and
caspase-3) that are capable of tau processing. Tau protein is
a substrate for calpain in vitro (Johnson et al., 1989; Litersky
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Yang and Ksiezak-Reding (1995) and Yen et al. (1999)
previously demonstrated that, under the in vitro digestion
paradigm, calpain produces N-terminal truncation as well as a
cleavage approx. 100 residues from the C-terminal of full-
length four-repeat human tau (441 residues). Park and
Ferreira (2005) reported that calpain could in fact produce
a neurotoxic 17-kDa tau fragment. Zhang JY et al. (2009)
also showed that autophagy inhibition in rat brain also
cause tau proteolysis by calpain. Yet, specific calpain cleavage
sites in tau protein have never been reported. Tau is also
cleaved by caspase-3 in cultured neuronal cells under the
apoptotic paradigms that mimic neurodegeneration (Canu
et al., 1998; Chung et al., 2001; Rohn et al., 2002;
Krishnamurthy and Sneige, 2002; Gamblin et al., 2003). It
was further determined that tau was cleaved by caspase-3 in
vitro at two major cleavage sites: between Asp
25 and Gln
26
and between Asp
421 and Ser
422 in human tau (Chung et al.,
2001; Rohn et al., 2002). In rat, the first cleavage sequence is
not conserved. Tau truncated at Asp
421 is also found as a
component of neurofibrillary tangle of Alzheimer’s brain
(Guillozet-Bongaarts et al., 2005).
In TBI and ischaemic brain injury, axons are highly
vulnerable neuronal structures to mechanical and chemical
insults (e.g. sodium and calcium homoeostasis disturbances)
and excitotoxicity to the brain. Evidence of axonal damage
following TBI hasbeendocumented extensively, and prolonged
and sustained loss of white matter (Gale et al., 1995; Bramlett
and Dietrich, 2002) and increased demyelination (Ng et al.,
1994; Gale et al., 1995) have been detected, although the
underlying biochemical mechanisms are not completely
understood. Structurally, the damaged axon undergoes
progressive changes including swelling, vacuolization and,
occasionally, disconnection and fragmentation. Ultrastructural
features, such as neurofilament compaction, misalignment and
disassembly, microtubule loss, increased axolemmal permeab-
ility and mitochondrial swelling and disruption of cristae also
occur (Christman et al., 1994; Pettus et al., 1994; Buki et al.,
1999,2000).TAI(traumaticaxonalinjury)isa consequenceofa
cascade of mechanical and biochemical events that have only
recently begun to be elucidated. Increased permeability of the
axolemma and subsequent Ca
2+ influx initiate the activation of
various proteases and mitochondrial dysfunction, leading to
degradation of the axonal cytoskeleton and disturbances in
axonal transport (Kampfl et al., 1997; Buki et al., 2000; Knoblach
et al., 2002; Medana and Esiri, 2003). Wallerian degeneration has
been documented following TBI in humans (Adams et al., 2000),
but not in rodents. While TAI is recognized as an important
pathological component of acute brain injury, the precise
biochemical mechanisms of TAI are unknown. The microtubule-
associated tau is preferentially localized in the axon (Binder et
al., 1985; Kosik and Finch, 1987) and tau degradation is
associated with axonal disruption (Higuchi et al., 2002).
In the present study, we sought to elucidate the major tau
cleavage sites produced by calpain. We also test the hypothesis
that tau protein might be differentially susceptible to proteolytic
attack by calpain and caspase-3 respectively depending on the
type of neurotoxic or neurodegenerative conditions.
MATERIALS AND METHODS
In vivo model of TBI
A CCI (controlled cortical impact) device was used to model
TBI in rats (Dixon et al., 1991; Pike et al., 1998). It generated
injured brain tissue including hippocampus and cortex. Adult
male (280–300 g) Sprague–Dawley rats (Harlan, Indianapolis,
IN, U.S.A.) were anaesthetized with 4% isoflurane in a carrier
gasof 1:1 O2/N2O(4min),followedbymaintenanceanaesthesia
of 2.5% isoflurane in the same carrier gas. Core body tem-
perature was monitored continuously by a rectal thermistor
probe and maintained at 37¡1˚C by placing an adjustable
temperature-controlled heating pad beneath the rats. Animals
were mounted in a stereotactic frame in a prone position and
secured by ear and incisor bars. A midline cranial incision was
made, the soft tissues reflected and a unilateral (ipsilateral to
site of impact) craniotomy (7 mm diameter) was performed
adjacent to the central suture, midway between bregma and
lambda. The dura matter was kept intact over the cortex. Brain
trauma is produced by impacting the right cortex (ipsilateral
cortex) with a 5 mm diameter aluminium impactor tip (housed
in a pneumatic cylinder) at a velocity of 3.5 m/s with a 1.6 mm
compression and 150 ms dwell time (compression duration).
These injuries are associated with different magnitudes of local
cortical contusion and more diffuse axonal damage. Velocity
was controlled by adjusting the pressure (compressed N2)
supplied to the pneumatic cylinder. Velocity and dwell time
were measured by a linear velocity displacement transducer
(Shaevitz
TM model 500 HR; Lucas, Detroit, MI, U.S.A.) that
produced an analogue signal that was recorded by a storage-
trace oscilloscope (BK Precision, model 2522B; Placentia, CA,
U.S.A.). Sham-injured control animals underwent identical
surgical procedures but did not receive an impact injury.
Appropriate pre- and post-injury management was maintained
toensurecompliancewithguidelinessetforthbytheUniversity
of Florida Institutional Animal Care and Use Committee and the
National Institutes of Health guidelines detailed in the Guide
for the Care and Use of Laboratory Animals. Different brain
tissueregionswerecollected ata maximumofeighttimepoints
(2, 6, 24 h, and 2, 3, 5, 7, 14 days) after CCI, as described below.
Brain tissue collection and preparation
At the appropriate time-points (2, 6, 24 h, and 2, 3, 5, 7, 14
days) after CCI, animals were anaesthetized and immediately
killed by decapitation. Brains were immediately removed,
rinsed with ice-cold PBS and halved. The five different brain
regions in right hemispheres (cerebrocortex, subcortical white
matter, hippocampus and corpus callosum) were rapidly
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gen and frozen at 280˚C until use. For the left hemisphere,
the same tissue as the right side was collected. For Western-
blot analysis, the brain samples were pulverized with a small
mortar and pestle set over dry ice to a fine powder. The
pulverized brain tissue powder was then lysed for 90 min at
4˚C with 50 mM Tris/HCl (pH 7.4), 5 mM EDTA, 1% (v/v) Triton
X-100, 1 mM DTT (dithiothreitol), 16protease inhibitor
cocktail (Roche Biochemicals). The brain lysates were then
centrifuged at 15000 g for 5 min at 4˚C to clear and remove
insoluble debris, snap-frozen and stored at 285˚C until used.
Rat primary cerebrocortical culture and
neurotoxic challenges
Cerebrocorticalcells harvested from1-day old Sprague–Dawley
rat brains were plated on poly-L-lysine coated on six-well
cultureplates(ErieScientific,Portsmouth,NH,U.S.A.)according
to a previously cited method (Nath et al., 1998) at a density of
4.36610
5 cells/ml. Cultures were maintained in DMEM
(Dulbecco’s modified Eagle’s medium) with 10% fetal bovine
serum in a humidified incubator in an atmosphere of 10% CO2
at 37˚C. After 5 days in culture, the medium was changed to
DMEM with 5% horse serum. Subsequent media changes were
performed thrice a week. Experiments were performed on days
10 to 11 in vitro when astroglia had formed a confluent
monolayer beneath morphologically mature neurons.
Neurotoxic challenges and pharmacologic intervention.
Inadditiontountreated controls,thefollowingconditionswere
used: NMDA (N-methyl-D-aspartate; 300 mM; Sigma) for 3–24
h as an excitotoxic challenge (Nath et al., 2000); apoptotic
inducers STS (staurosporine) (0.5 mM; Sigma, St. Louis, MO,
U.S.A.) that activates calpain and caspase-3 for 24 h (Zhang Z
et al., 2009); the Ca
2+ chelator EDTA (5 mM; Sigma) for up to
24 h as a caspase-dominated challenge (Waterhouse et al.,1996;
Chiesa et al., 1998; McGinnis et al., 1999; Zhang Z et al., 2009).
For pharmacological intervention, cultures were pretreated 1 h
before the STS, EDTA or NMDA challenge with the calpain
inhibitor SNJ-1945 (Senju Pharmaceuticals, Kobe, Japan)
(Shirasaki et al., 2005; Oka et al., 2006; Koumura et al., 2008),
or the pan-caspase inhibitor Z-VAD (OMe)-FMK (R&D,
Minneapolis, MN, U.S.A.). Cell lysates were collected and lysed
with the same lysis buffer as described above.
In vitro protease digestion of tau in naı ¨ve brain
lysate and pure recombinant rat tau
For these experiments, Brain tissue collection and preparation
are the same as described above, except without the use of
protease inhibitor cocktail (see above). In vitro protease
digestion of naı ¨ve rat hippocampus lysate (30 mg) or purified
recombinant human tau (Panvera Co., Madison, WI, U.S.A.)
with purified proteases, human calpain-2 (BD Bioscience,
Catalogue no. 208715, 1 mg/ml) and recombinant human
caspase-3 (BD Bioscience, 1 unit/ml) was performed in a
buffer containing 100 mM Tris/HCl (pH 7.4) and 20 mM DTT.
For calpain-2, 2 mM CaCl2 was also added, and then
incubated at room temperature (25˚C) for 30 min. In
addition, 2 mM EDTA was added for caspase-3 and the
mixture was incubated at 37˚C for 4 h. The protease reaction
was stopped by the addition of PAGE-sample buffer.
Generation of calpain and caspase-3-specific
TauBDP-antibodies
To ascertain whether tau fragments detected originated from
calpain or caspase-3 proteolysis, we raised TauBDP-45K
(caspase) and TauBDP-35K (calpain)-specific antibodies. A
synthetic peptide (Cys-C6-SIDMVD-COOH) based on tau C-
terminal of tauBDP-45K generated by caspase-3 (Chung
et al., 2001) and another peptide (NH2-KDRTGN-C6-Cys)
based on the new N-terminal of the calpain-mediated
TauBDP-35K were custom made (California Peptide, Napa,
CA, U.S.A.). A C6 linker and N-terminal cysteine were
introduced for the subsequent coupling of the peptide to
KLH (keyhole limpet haemocyanin) protein using a sulfo-link
cross-linking reagent (Pierce). After coupling efficiency
determinations, peptides were dialysed, concentrated, and 2
mg of conjugated protein was used for multiple antigen
injections into two rabbits. After 3 months, collected serum
samples from the rabbits were subjected to affinity
purification using the same synthetic peptide coupled to
sulfo-linked resins (Pierce). Affinity-purified antibody was
dialysed against TBS (20 mM Tris/HCl, pH 7.4 and 150 mM
NaCl), before it was concentrated and stored in 50% glycerol
at 220˚C.
Immunoblotting analysis
After SDS/PAGE in a Tris/glycine buffer system and electro-
transfer, blotting membranes were blocked for 1 h at ambient
temperature in 5% (w/v) non-fat dried skimmed milk powder in
TBST (TBS and 0.05% Tween-2), then incubated in primary
monoclonal tau antibody (Cedarlane, Tau-1, catalogue no.
CLT9007) in TBST with 5% milk at 1:50 dilution as recommended
by the manufacturer at 4˚C overnight. This was followed by three
washes with TBST and a 2 h incubation at ambient temperature
with a secondary antibody linked to biotinylated secondary
antibody (Amersham, catalogue no. RPN1177v1) followed by a
30 min incubation with streptavidin-conjugated alkaline phos-
phatase (colorimetric method). Then a colorimetric development
was performed with a one-step BCIP (5-bromo-4-chloroindol-3-
yl phosphate)/NBT (Nitro Blue Tetrazolium) reagent (KPL,
catalogue no. 50-81-08). Molecular masses of intact tau protein
and its potential breakdown products (TauBDPs) were assessed by
running alongside rainbow-coloured molecular-mass standards
(Amersham, catalogue no. RPN800V). When desired, Western
blots were probed with polyclonal antibody specific to anti-
activated calpain-1 new N-terminal (anti-NH2-LGRHENA) or
pro-calpain-2 N-terminal (anti-SHERAIK). Results shown are
Calpain- and caspase-mediated tau proteolysis
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27representative of three separate experiments. Semi-quantitative
evaluation of tau protein TauBDPs levels were performed via
computer-assisted densitometric scanning (Epson XL3500 high-
resolution flatbed scanner) and image analysis with Image J
software [NIH (National Institutes of Health)]. Uneven loading of
samples into different wells might occur despite careful protein
concentration determination and careful sample handling and
gel loading (20 mg per well). To overcome this source of vari-
ability, we performed Western blotting using the same sample
against b-actin (monoclonal, Sigma, no. A5441) as a control.
Statistical analyses
Densitometric results were acquired in arbitrary densito-
metric units. Changes in any outcome parameter were
compared with the appropriate control group. Thus, mag-
nitude of change from control in one model system could be
directly compared with magnitude of change from any other
model system. In this study, six replicate results were
evaluated by Student’s t test and ANOVA and post-hoc
Tukey tests. A value of P,0.05 was taken as significant.
RESULTS
Identification of major calpain cleavage sites in
rat tau protein and validating tau-fragment-
specific antibodies
While the two major caspase-3 cleavage sites (Asp
25QGln
26
and between Asp
421QSer
422) in human tau (4R isoform)
has been mapped out (Chung et al., 2001; Rohn et al., 2002),
with the C-terminal cleavage site conserved in rat tau
(4R isoform) (Asp
412QSer
413), the exact calpain cleavage
sites have not been identified. We subjected recombinant
rat tau (441-residue four-repeat isoform) with calpain-2 at
two different protease/substrate ratios: 1:100 and 1:200
and calpain-1 at 1:100 (Figure 1). A number of fragments
can be visualized by Coomassie Brilliant Blue staining. Both
calpain-1 and -2 generated major tau fragments of the
same size. We subjected these fragments to N-terminal
microsequencing and were able to identify the internal
N-terminal sequence of three peptide fragments: TauBDP-
35K (band A), TauBDP-25K (band B) and TauBDP-15K (band
C). They yielded newly exposed N-terminal of NH2-
KDRTGNDEKK, NH2-PTREPKKVAVV and NH2-ENAKAKTDHGA,
corresponding to cleavage sites between Ser
130QLys
131;
Gly
157QAla
158 and Arg
380QGlu
381 respectively (Figure 1).
This multiple cleavage breakdown pattern is consistent with
previous studies on calpain proteolysis of tau (Johnson et al.,
1989;Litersky et al., 1993; Yang and Ksiezak-Reding,1995; Yen
et al., 1999).
With this new information, in Figure 2, we mapped out the
various cleavage sites and the corresponding Tau-BSPs that are
produced. In addition, to readily distinguish calpain-mediated
TauBDP versus caspase-mediated Tb-BDP formation, we de-
veloped fragment-specific antibodies to target the major
calpain-mediated TauBDP-35K (35 kDa tau-breakdown prod-
uct) (based on neo-N-terminal peptide NH2-KDRTGN), and the
caspase-mediated TauBDP-45K (based on neo-C-terminal
peptide GSIDMVD-COOH) respectively (Figure 2).
To validate the fidelity of these two fragment-specific
antibody tools, we subjected rat tau protein in small quan-
tities (100 ng) to either calpain-2 or caspase-3 digestion. We
then probed untreated rat tau and digested tau samples by
SDS/PAGE followed by immunoblotting with total tau,
Figure 1 Purified rat tau fragmentation by calpain
Recombinant rat tau protein (50 mg) was digested in vitro by human calpain-1 (at protease/substrate ratio of 1:100) or rat calpain-2
(at protease/substrate ratios of 1:100 and 1:200). Intact protein and tau fragments were resolved by SDS/PAGE and transferred to
PVDF membrane. Proteins were visualized by Coomassie Brilliant Blue staining. Both calpain-1 and -2 generated major tau fragments
of the same size. Several major fragments (A, B and C) were subjected to Edman N-terminal microsequencing. The table shows the
identified in vitro calpain cleavage sites of rat tau.
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calpain-1 and -2 digested tau into several immunoreactive
fragments (42, 35 and 15 kDa), while caspase-3 digestion only
produced limited fragment doublet of 48 kDa/45 kDa
(Figure 3). Probing with TauBDP-35K (calpain) and TauBDP-
45K (caspase) antibodies confirmed that these antibodies are
fragment specific with no cross-reactivity with intact protein
or other fragments (Figure 3).
Examining tau protein integrity in cultured
cerebrocortical neurons subjected to neurotoxic
and neurodegenerative conditions
Next, a number of neurotoxic conditions were carefully selec-
ted to reflect excitotoxicity (mixed necrosis and apoptosis) and
two apoptosis-inducing agents that evokes and cal-
pain and/or caspase activation to mimic neurodegenerative
conditions. In our design, rat cerebrocortical cultures were
Figure 2 Schematic of tau proteolysis by the calpain and caspase-3 pathways
In this model, rat tau-4 repeat (4R) isoform with 432 residues is shown. It has four microtubule (MT)-binding repeats. Caspase-3
cleaves near the C-terminal (at Asp
412QSer
413), and an unknown N-terminal site producing key caspase fragment doublet of 45–48
kDa (TauBDP-45K). On the other hand, calpain cleaves at least three internal sites (Ser
120QLys
121; Pro
209QPro
2108 and
Arg
380QGlu
381) producing a key calpain fragment of 35 kDa (TauBDP-35K)
Figure 3 Tau protein in rat brain lysate is sensitive to in vitro calpain and caspase-3 digestion
The lysate of naı ¨ve rat hippocampus was in vitro cleaved by calpain-1, calpain-2 and caspase-3: Control; Calpain-1 (1:500 protease/
substrate ratio); calpain-2; (1:200 protease/substrate ratio); or caspase-3 digestion (1:50 protease/substrate ratio). The pattern of the
tau protein fragmentation was monitored with total tau antibody (A) or antibodies specific to caspase-mediated TauBDP-45K (B)a n d
calpain-mediated TauBDP-35K (C) respectively.
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29treated as an excitotoxic challenge NMDA (Nath et al., 1998);
apoptotic inducer STS (0.5 mM) that activates calpain and
caspase-3 for 24 h (Zhang Z et al., 2009); the Ca
2+ chelator
EDTA as a caspase-dominated challenge (Waterhouse et al.,
1996; Chiesa et al., 1998; McGinnis et al., 1999; Zhang Z et al.,
2009), percentage neuronal necrosis and percentage apoptosis
werealso assessedbyusingpropidiumiodidelabellingofnuclei
at 24 h for necrosis, while Hoechst 33342 stained condensed
nuclear DNA as evidence for % apoptosis. Figure 4(A) shows
NMDA, EDTA and STS treatments all caused extensive neurode-
generation in vitro. Figure 4(B) further shows that, while NMDA
induced a mixed necrosis/apoptosis phenotype, while both STS
and EDTA produced a robust apoptosis phenotype.
We then investigated the relative contributions of cal-
pain and caspase-3 in the fragmentation of tau in cultured
neurons under several neurodegenerative conditions. With
NMDA treatment, tau is significantly degraded into multiple
fragments (42K, 35K and 15K) including a dominant signal of
calpain-mediated TauBDP-35K with minimal caspase-
mediated TauBDP-45K (Figure 5, top three panels).
When caspase inhibitor (Z-VAD; 20 mM) was added to the
NMDA condition, no significant changes of tau breakdown
pattern were observed. In contrast, when inhibitor (SNJ-1945;
20 mM) was added to the NMDA condition, it significantly
reduced the lower-molecular-mass fragment, including com-
plete blockade of the calpain-mediated TauBDP-35K (Figure 5,
top and third panels), and yet some high-molecular-mass
fragments (425–48K) persisted. Interestingly, when a blot was
probed with the anti-caspase-mediated TauBDP-45K antibody,
TauBDP-45K/48Kweredetectedin the calpain inhibitor-NMDA
co-treatment lane (Figure 5, second panel). Consistent with
the above, when established calpain/caspase dual-substrate
Figure 4 Tau fragmentation pattern in neurotoxin-challenged rat
cerebrocortical neurons and the contribution of calpain and/or caspase
Rat cerebrocortical cultures were either untreated (control), or treated with
excitotoxin (NMDA, 200 mM), apoptosis-inducers calcium chelator EDTA (2 mM) or
STS (0.5 mM) for 24 h. (A) All three neurotoxic conditions cause extensive
neurodegeneration when observed by phase contrast microscopy. (B)P e r c e n t a g e
neuronal necrosis and percentage apoptosis were also assessed by using propidium
iodine labelling of nuclei at 24 h for necrosis, while Hoechst 33342 stained
condensed nuclear DNA as evidence for percentage apoptosis, using Genescript
Double Stain Apoptosis Detection Kit (Hoechst 33342/PI). Shown are means¡S.D.
(n55). *Indicates statistical significance (P50.05; Student’s two-tailed t test).
Figure 5 Tau fragmentation pattern in neurotoxin-challenged rat cerebrocortical neurons and the contribution of calpain and/or
caspase
Rat cerebrocortical cultures were either untreated (control), or treated with excitotoxin (NMDA, 200 mM), apoptosis-inducer calcium
chelator EDTA (2 mM) or STS (0.5 mM) for 24 h. For tau fragmentation analysis, neurotoxin challenges were undertaken in the
absence of presence of either calpain inhibitor SNJ-1945 (20 mM) or caspase inhibitor Z-VAD-FMK (20 mM). After 24 h, cell lysates
were harvested for protein and immunoblotting analysis with total tau monoclonal antibody (top panel), antibody specific to
caspase-mediated TauBDP-45K (second panel), antibody specific to calpain-mediated TauBDP-35K (third panel) or aII-spectrin
monoclonal antibody (bottom panel). Results shown are representative of three separate experiments.
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NMDA-yielded prominent calpain-mediated SBDP150/
SBDP145, with minor bands of caspase-3-mediated SBDP120
(Figure 5, bottom panel). These fragments are strongly
inhibited with their respective protease inhibitors (SNJ and
Z-VAD). Taken together, these results suggest that in NMDA
paradigm, calpain is the dominant pathway in tau fragmenta-
tion with a more minor contribution of caspase.
When the neuronal culture was treated with apoptosis-
inducing EDTA, tau was truncated only to TauBDP-48K/45K,
as confirmed by total tau blot and caspase-mediated anti-
TauBDP-45K blot (Figure 5, top two panels). Both fragments,
as expected are caspase inhibitor (Z-VAD) sensitive, but
insensitive to calpain inhibitor (SNJ-1945) (Figure 5). Thus,
EDTA challenge produced a straight caspase-dominant tau
fragmentation condition. The aII-spectrin breakdown pattern
again confirmed the presence of caspase-mediated SBDP120,
but not calpain-generated fragment SBDP145 (Figure 5,
bottom panel).
Whentheculturewastreatedwithanotherapoptosisinducer,
STS, a balance of higher-molecular-mass (45--48 kDa) and low-
molecular-mass (35 and 15 kDa) TauBDPs were observed
(Figure 5, top panel). The 48/45K fragments were caspase-
mediated, as confirmed by the tau-45K fragment-specific
antibody blot as well as its sensitivity to caspase inhibitor (Z-
VAD) (Figure 5, second panel). Similarly, the involvement of
calpain was confirmed by the TauBDP-35K-specific antibody
and its sensitivity to calpain inhibitor SNJ-1945 (Figure 5, third
panel). Importantly, the presence of calpain inhibitor strongly
elevated the TauBDP-48K/45K by both total tau blot and anti-
TauBDP-48/45K blot (Figure 5, second panel), suggesting the
dual involvement of both calpain and caspase. This is also
consistent with aII-spectrin breakdown pattern. Calpain inhib-
itor blocked mainly the SBDP145, but not the SBDP120, while
the caspase inhibitor blocked the SBDP120, but not SBDP145. It
is noted that both inhibitors failed to block the formation of
SBDP150, as both calpain and caspase can produce an SBDP150
of almost identical molecular mass (Wang, 2000) (Figure 5B,
bottom panel). Taken together, with STS treatment produces a
neurodegenerative paradigm where there is a dual and balanced
contribution of both calpain and caspase in tau fragmentation.
Immunoblot analysis of tau protein integrity in
rat brain after experimental TBI
TBI is a risk factor for subsequent development of AD. Thus,
we were interested in the tau fragmentation process under
this acute neurodegenerative condition. We hypothesize that
such tau fragmentation might have downstream conse-
quences leading to tauopathy and possible development of
AD. We subjected rats to CCI (controlled cortical impact), an
experimental model of TBI, as previously established (Pike
et al., 1998). We then harvested cortical and hippocampal
tissues for immunoblotting examination with antibodies
against total tau protein (Figure 6), specific to calpain-
mediated TauBDP-35K and caspase-mediated TauBDP-45K
respectively (Figure 7). We have previously detected signifi-
cant aII-spectrin breakdown products in the traumatic
injured rat brain (Pike et al., 1998).
In the naı ¨ve cortex, tau protein was detected by immuno-
blots as a cluster of bands approx. 52–68 kDa, most likely
representing the various isoforms and phosphorylation states
of tau protein (Figure 6). Sham (24 h after craniotomy) did
not significantly generate TauBDPs. Next, we examined the
temporal profile of TBI-induced tau proteolysis in the rat
cortex. In the rat ipsilateral cortex of the TBI group,
immunoblots revealed that TauBDP-35K and TauBDP-15K
accumulated relatively rapidly, followed by the delayed
appearance of TauBDP-25K (Figure 6A). When the density
of two TauBDPs of the TBI group was compared with the
naı ¨ve group, the results showed that the TauBDP-15K
increased rapidly, as early as 2 h after TBI, and sustained
over 48 h, followed by its resolution for 3–14 days
(Figures 6A and 6B). On the other hand, TauBDP-25K, while
significantly elevated in 2–6 h, did not reach its peak until 48
h and this level was sustained until at least 7 days (Figure 6B).
Other fragments (such as TauBDP-45K) can be observed, but
they are minor fragments (Figure 6A). Furthermore, we
routinely performed b-actin blots as controls and found
even sample loading (see Figure 6A). In addition, in the
contralateral cortex, no tau proteolysis was observed in all
three groups, even when tau immunoblots were intentionally
overdeveloped (results not shown).
The rat hippocampus is another highly vulnerable region
following experimental TBI. In the naı ¨ve and sham hippocam-
pus,tauisexpressed againasa cluster ofisoformsof52–68 kDa
(Figure 6C). In the rat ipsilateral hippocampus of the TBI group,
tau immunoblots revealed the accumulation of two fragments
(TauBDP-35K and TauBDP-15K) from 2 h to 5 days after TBI
(Figure 6C). When the density of TauBDP-35K and TauBDP-15K
of TBI group was compared with the naı ¨ve group, the results
showed that both TauBDPs rose as early as 2–6 h after TBI,
peaked at 1–2 days and were sustained over 5 days (Figure 6D).
To further distinguish if any of these fragments were
derived from calpain and/or caspase proteolysis, we employed
the two tau-fragment-specific antibodies. In the injured
cortex, we found robust signals of calpain-mediated TauBDP-
35K from 2 h to 5 days, receding in 5 and 7 days (Figure 7A).
In contrast, we only observed a faint caspase-mediated
TauBDP-45K signal (from 1 to 7 days) on overexposure of the
blot development (Figure 7A). In the injured hippocampus,
the TauBDP-35K signal was again very robust from 6 h to
7 days, while TauBDP-45K was not detectable (Figure 7B).
These results suggest that CCI-induced neurodegeneration
is accompanied by the formation and accumulation of
calpain-mediated TauBDPs with only minor contributions to
caspase-generated tau fragments in the injured cortex.
In addition, we also sought to compare tauBDP-35K
formation with calpain-1 and calpain-2 temporal activation
profiles. To do this, we employed anti-activated calpain-1
new-N-terminal (anti-NH2-LGRHENA) antibody (A), or pro-
calpain-2 N-terminal (anti-SHERAIK) antibody. Figure 8 shows
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31Figure 7 Examination of relative contribution of calpains versus caspase-3 in tau proteolysis in rat cortex and hippocampus following
TBI with tau-fragment-specific antibodies
Western blot of naı ¨ve and CCI cortex (A) and hippocampus (B) time course samples similar to those of Figure 5. However, these blots
were probed with polyclonal antibody specific to caspase-mediated TauBDP-45K (lower panel), or polyclonal antibody specific to
calpain-mediated TauBDP-35K (upper panel). Results shown are representative of three separate experiments.
Figure 6 Time course of tau protein fragmentation in rat cortex and hippocampus following TBI
Western blot results show TauBDP-35K, TauBDP-25K and TauBDP-15K accumulated in injured rat cortex following TBI at various
time points (A). The densitometric results revealed that TauBDP-35 K/15K and TauBDP-25K accumulated in the different time points
after TBI (B). In the injured rat hippocampus, immunoblots revealed tau TauBDP-35K and TauBDP-15K are the key fragments and
they accumulated in a similar temporal profile in the TBI group (C), (*P,0.05; **P,0.001) when compared with naı ¨ve group (D).
b-Actin blots were also performed routinely as protein-loading evenness controls, thus ruling out technical artefacts. Results are
from n56( B, D). Student’s t test was used to compare TBI time points with naı ¨ve (*P,0.05; **P,0.001).
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autolytically activated in injured cortex. Calpain-1 has an early
peak on day 2 and 3 and subsided afterward, while calpain-2
also peaked on day 2 but was sustained to 3 and 5 days
(Figure 8). The calpain-1 activation matches very well with the
appearance of TauBDP-35K (calpain-specific) that also peaked
atday2and3ininjuredcortex(Figure 7).Takentogether,these
results argue that calpain-1 might be the major isoform
cleaving tau.
Suppression of TauBDP-35K by calpain inhibitor
administration in vivo
Finally, to ascertain that the prominent TauBDP-35K generated
after CCI was indeed calpain-mediated, we administered a
calpain-specific inhibitor agent (SNJ-1945) (Shirasaki et al.,
2005; Oka et al., 2006; Koumura et al., 2008) (100 mg/kg, i.v.
bolus) immediately after CCI. Cortical tissue was probed with
a TauBDP-35K-specific antibody (Figure 9). Densitometric
analysis shows that SNJ-1945 was effective in suppressing
TBI-induced TauBDP-35K by 60% (P,0.035, Student unpaired
t test).
DISCUSSION
Tau protein is a major neuronal microtubule-associated
protein primarily localized in the axonal compartment of
neurons (Kosik and Finch, 1987). Owing to the presence of
several alternative splicing sites and multiple phosphorylation
sites, tau protein usually appears on immunoblots as multiple
bands of approx. 52–68 kDa. Under normal conditions, tau
promotes tubulin assembly and stability and is involved in
axon elongation and transport (Garcia and Cleveland, 2001;
Avila et al., 2004). Tau interacts with microtubules at the
tubulin-binding domain to induce tubulin assembly, stabilizes
the polymer and minimizes microtubule disassembly
(reviewed by Garcia and Cleveland, 2001; Drubin and
Kirschner, 1986). Tau abnormality is linked to several neuro-
degenerative disorders referred to as ‘tau pathologies’, a
heterogeneous group of age-dependent cognitive disorders,
most notably AD and CTE (chronic traumatic encephalopathy;
reviewed by Garcia and Cleveland, 2001). Axonally specific
microtubule-associated protein tau is an important factor in
AD as tau aggregate is found in a form of neurofibrillary
tangle. Besides hyperphosphorylation, proteolytic processing
of tau was suggested to facilitate this tau deposit formation
(Zemlan et al., 2003; Gabbita et al., 2005; Arnaud et al., 2009).
Similarly, tau is degraded following acute TBI and with
neurotoxin exposure (e.g. Methamphetamine) (Warren et al.,
2005, 2007; Arnaud et al., 2009). Both cellular cysteine
proteases (calpain and caspase-3) are capable of tau
processing. In addition, there is now mounting evidence that
repeated concussion (or mild TBI) experienced by impact sport
athletes (e.g. football and hockey players and boxers) can lead
to a brain disorder called CTE – a tauopathy disease not
dissimilar to the tau pathological component of AD (McKee et
al., 2009). In addition, there are epidemiological data linking
prior TBI (especially among males) to increased risk of
developing AD later in life (Van Den Heuvel et al., 2007; Kiraly
and Kiraly, 2007). Thus, it is possible that tau fragmentation
in acute brain injury will somehow facilitate or enable tau
aggregate deposit formation (Yoshiyama et al., 2005; Uryu
et al., 2007).
Calpain and caspase-3 cysteine proteases are important
mediators of cell death and dysfunction in numerous CNS
(central nervous system) diseases and injuries, including TBI
(McIntosh et al., 1996; Bartus, 1997; McCracken et al., 1999;
Figure 8 Examination of autolytic activation of calpain-1 and calpain-2
in rat cortex following TBI
Western blot of naı ¨ve and cortex CCI time course samples similar to those in
Figure 6. However, these blots were probed with polyclonal antibody specific
to anti-activated calpain-1 new N-terminal (anti-NH2-LGRHENA) (A), or pro-
calpain-2 N-terminal (anti-SHERAIK) (B). Results shown are representative of
three separate experiments.
Figure 9 Attenuation of calpain-generated TauBDP-35K after CCI by
administration of calpain inhibitor in vivo
Ipsilateral cortical tissue lysate were probed with anti-TauBDP-35K antibody
6 h after controlled cortical impact [1.6 mm with a calpain inhibitor SNJ-
1945 (100 mg/kg bolus, i.v.) given immediately after CCI]. Top panel: representative
immunoblots [naı ¨ve (N) control was also shown]. (B) Quantification of TauBDP-
35K levels (n55) shown are means¡S.D. #Indicates statistical significance
(P50.035; Student’s two-tailed t test).
Calpain- and caspase-mediated tau proteolysis
E 2011 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
33Wang, 2000; Pike et al., 2004). There is also evidence of
calpain and caspase-3 activation in injured axons following
experimentalTBI (Saatman et al., 1996a;Newcomb et al., 1997;
Pike et al., 1998; Buki et al., 1999, 2000; Beer et al., 2000). In
addition, inhibitors of both calpains and caspase-3 can confer
neuroprotection after TBI in animal models (Nath et al., 1996;
Saatman et al., 1996b, 2000; Posmantur et al., 1997; Clark
et al., 2000). Tau is vulnerable to both of these proteases
in vitro (Yang and Ksiezak-Reding, 1995; Yen et al., 1999;
Chunget al., 2001; Rohn et al., 2002;Gamblin et al., 2003; Park
and Ferreira, 2005; Guillozet-Bongaarts et al., 2005; Delobel
et al., 2005; Arnaud et al., 2009). The major cleavage site for
caspase-3 on rat tau has been mapped out at the C-terminal
Asp
412Q Ser
413 (Rohn et al., 2002; Gamblin et al., 2003), while
calpain produces multiple fragments including a neurotoxic
fragment of 17 kDa (Park and Ferreira, 2005), but exact calpain
cleavage sites remained elusive.
In the present study, the primary objective was to examine
the relative vulnerability of tau to calpain and caspase-3
attack under neurotoxic and neurodegenerative conditions.
We first identified three major calpain cleavage sites in rat
tau (four-repeat 442-residue isoform) as Ser
130QLys
131,
Gly
157QAla
158 and Arg
380QGlu
381 (Figures 1 and 2). We
then developed fragment-specific antibodies to target the
major calpain-mediated TauBDP-35K as well as the major
caspase-mediated TauBDP-45K respectively (Figure 3).
In rat cerebrocortical culture treated with excitotoxin
(NMDA), tau is significantly degraded into multiple fragments,
including a dominant signal of calpain-mediated TauBDP-35K
with minimal caspase-mediated TauBDP-45K (Figure 4). When
cultures were treated with apoptosis-inducing EDTA, tau was
truncated only to TauBDP-48K/45K, which are both caspase
inhibitor sensitive. Cultures treated with another apoptosis
inducingSTS, dual fragmentationby calpain(TauBDP-35K)and
caspase-3 (TauBDP-45K) was observed (Figure 5).
Our results revealed that 52–68 kDa tau protein in lysate
from naı ¨ve rat hippocampus was degraded in vitro into main
smaller fragments (TauBDP-35K, -25K and -15K) by calpain-2
and large fragments (TauBDP-45/48K) by caspase-3. Thus, the
calpain-mediated tau protein fragmentation pattern in vitro
(TauBDP-35K, -25K and -15K) (Figure 3) matched very well
with in vivo tau proteolysis after TBI (Figure 6). We also noted a
TauBDP-15K invitro, incellcultureand invivo(Figures 3, 5 and
6) might correspond to the 17 kDa calpain fragment reported
previously (Park and Ferreira, 2005). In addition, the antibody
specific to the calpain-mediated TauBDP-35K readily detected
this fragment in both injured cortex and hippocampus for
sustained post-TBI intervals (Figure 7). Since the controlled
cortical impact device targets the cortex, there was more focal
injury in the ipsilateral cortex tissue than in the hippocampal
tissue, which was impacted indirectly by contusive force. As a
result,there is more extensive tau proteolysis in the cortex than
in the hippocampus (Figure 7). Equally importantly, TauBDP-
35K generated after CCI was suppressed by systemic admin-
istration of calpain-specific inhibitor agent (SNJ-1945)
(Figure 9). These results are consistent with those reported by
Sinjoanu et al. (2008) that calpain inhibitor A-705253 inhibits
b-amyloid-induced tau cleavage in hippocampal neurons.
Regarding the contribution of caspase to tau fragmentation
in vivo, we know that rat tau is cleaved by caspase-3 between
Asp
412 and Ser
413 (Chung et al., 2001; Rohn et al., 2002). Since
this cleavage produced large TauBDPs of 45K/48K (Figure 3),
almost indistinguishable from the intact tau clusters, it was
difficult to ascertain whether these fragments were detected
in TBI using total tau antibody (Figure 5). Therefore, we
developed an antibody (anti-TauBDP-45K) that only detected
the caspase-3 generated new tau C-terminal (SSTGSIDMVD-
COOH), but does not recognize the intact tau or calpain-
produced TauBDPs (Figures 2 and 3). Using this fragment-
specific antibody, we observed that the caspase-3-generated
TauBDP-45K/48K was readily detected during in vitro caspase-
3 digestion (Figure 3), but was only minimally detected in
injured cortex in vivo after TBI (upon overdevelopment of the
blot) (Figure 6). Taken together, these results strongly suggest
that tau protein is primarily attacked in vivo by calpain with
only minor contributions by caspase-3 following TBI in rats.
This is in contrast to chronic neurodegenerative paradigms
where tau is cleaved more prominently by caspase-3 (Canu
et al., 1998; Chung et al., 2001; Rohn et al., 2002;
Krishnamurthy and Sneige, 2002). In addition, more minor
caspase-3 activity in our TBI model could in fact be due to
someinhibitorypathwayfor caspase. Also,caspase-3expressed
athighlevelsin brainfromfetal ratsandratpups,butis down-
regulated in adult rats (Shimohama et al., 1999), possibly
explaining the low TauBDP-45K levels in vivo after brain injury
(Figure 6),whilein ratin vitro cultures(14div),therewasmore
caspase-3 participation (Figure 5).
In summary, following acute brain injury, tau protein is
predominantly vulnerable to calpain attack following acute
TBI with minor contributions by caspase. Yet, in cultured
neurons, different acute neurotoxic challenges result in
various degrees of calpain and caspase contributions in tau
fragmentation. Thus, caution should be exercised when
studying tau fragmentation. Employing calpain- and cas-
pase-generated tau fragment-specific tools will add to the
fidelity of such tau fragmentation analysis. In addition, if
preserving tau integrity is a therapeutic goal, depending on
the pathological condition, one might consider the use of
calpain and/or caspase inhibitory agents. Lastly, to study the
possible linkage between acute head trauma and subsequent
development of tauopathy (CTE and AD), it will be very
important to examine if the calpain-generated TauBDP-35K,
in addition to caspase-generated TauBDP-45K, can be
detected in aggregated tau or neurofibrillary tangles. These
efforts are now ongoing in our laboratories.
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